300813SZSE

Response Report from Zhejiang Tailin Biotechnology Co., Ltd. and Great Wall Securities Co., Ltd. Regarding the Inquiry Letter on the Issuance of Convertible Bonds to Unspecified Objects

Tailin Biotechnology Co., Ltd.·June 3, 2026·146 pages

✨ AI Summary

This report addresses the inquiry from the Shenzhen Stock Exchange regarding Zhejiang Tailin Biotechnology's plan to issue convertible bonds. Key figures include a projected annual revenue of 29.7 million RMB from the new project and a net profit margin of 16.53%. The report outlines the company's financial performance, market conditions, and the sustainability of future revenue growth.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Response to the Inquiry Letter

1. Acknowledgment of Inquiry

Shenzhen Stock Exchange: We acknowledge receipt of your inquiry letter dated May 19, 2026, regarding Zhejiang Tailin Biotechnology Co., Ltd.'s application to issue convertible bonds to unspecified objects (Inquiry Letter No. [2026] 020044).

2. Company Overview

Zhejiang Tailin Biotechnology Co., Ltd. (hereinafter referred to as "the issuer," "the company," or "Tailin Biotechnology") has discussed the issues raised in the inquiry letter with Great Wall Securities Co., Ltd. (hereinafter referred to as "Great Wall Securities" or "the sponsor"), Tianjian Accounting Firm (Special General Partnership) (hereinafter referred to as "the issuer's accountant" or "Tianjian"), and Guohao Law Firm (Hangzhou) (hereinafter referred to as "the issuer's lawyer" or "Guohao"). We have verified the relevant matters and hereby provide the following detailed explanations for your review.

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.